<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636648</url>
  </required_header>
  <id_info>
    <org_study_id>En_2012</org_study_id>
    <nct_id>NCT01636648</nct_id>
  </id_info>
  <brief_title>Enable I Long-term Follow-up Study</brief_title>
  <official_title>Enable I Long-term Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, multi-center, non-interventional post-market study.
      The study is a post-market long-term follow-up study based on the same cohort of patients
      (148 patients) enrolled in a previous investigational study from March 2007 to December 2009
      (ATS 3f Enable™ Aortic Bioprosthesis Model 6000, number S2005) involving 10 European sites.
      Patient follow-up will take place on a yearly basis up to 10 years after the
      implant/enrollment. Medtronic ATS Inc. retains the right to terminate this study at any time
      after the 5 year followup.

      The primary objective of this study is to evaluate the safety and effectiveness of the
      Medtronic ATS Enable Aortic Bioprosthesis during long-term follow-up.

      As this is an observational study, safety and efficacy data will be summarized and
      described. There is no statistically powered study hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety and effectiveness</measure>
    <time_frame>10 years after implant</time_frame>
    <description>The primary objectives are to evaluate long-term safety and effectiveness of the Medtronic ATS Enable™ Aortic Bioprosthesis. Migration will be determined via echocardiographic assessment. Serious Adverse Events (SAE), Serious Adverse Device Effects (SADE), Adverse Device Effects (ADE) and Unanticipated Adverse Device Effects (UADE) will be reviewed by the Safety team and properly reported to Ethics Committees (EC) and Competent Authorities (CA) and Field Assurance if necessary/applicable.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortic Valve Replacement</intervention_name>
    <description>Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were enrolled and implanted during the previous investigational study named
        &quot;ATS 3f Enable™ Aortic Bioprosthesis Model 6000&quot; (study number S2005).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were enrolled and implanted for the ATS 3f Enable™ Aortic Bioprosthesis
             Model 6000, number S2005

          -  Patient willing to sign the new Data Release form (DRF) or Patient Informed Consent
             (PIC) for the post-market study (what is applicable for the study due to local
             requirements and regulations)

        Exclusion Criteria:

          -  ATS 3f Enable™ Aortic Bioprosthesis Model 6000 was explanted

          -  Patient died

          -  Patient lost to follow-up

          -  Patient withdrew
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagellonian University, John Paul the II Hospital</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Martens S, Sadowski J, Eckstein FS, Bartus K, Kapelak B, Sievers HH, Schlensak C, Carrel T. Clinical experience with the ATS 3f Enable® Sutureless Bioprosthesis. Eur J Cardiothorac Surg. 2011 Sep;40(3):749-55. doi: 10.1016/j.ejcts.2010.12.068. Epub 2011 Feb 20.</citation>
    <PMID>21342776</PMID>
  </reference>
  <reference>
    <citation>Englberger L, Carrel TP, Doss M, Sadowski J, Bartus K, Eckstein FF, Asch FM, Martens S. Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1681-7. doi: 10.1016/j.jtcvs.2014.03.054. Epub 2014 Apr 4.</citation>
    <PMID>24787699</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>July 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Replacement</keyword>
  <keyword>Aortic Valve Bioprosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
